Atlas Trials

The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002

Clinical trial NCT05928468 · UNKNOWN

Trial details

NCT number
NCT05928468
Sponsor
Guangzhou Patronus Biotech Co., Ltd.
Status
UNKNOWN
Phase
Early Phase 1
Study type
INTERVENTIONAL
COVID-19
Start date
2023-04-25
Primary completion
2023-07-31
Enrollment
210

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.